Solid Biosciences to acquire AavantiBio; announces $75M private placement

Solid Biosciences Inc.

Merger: Solid acquires AavantiBio through transitory subsidiary merger; AavantiBio survives as wholly owned.
Private placement of 159,574,463 shares at $0.47/share for ~$75M from accredited investors.
Closing requires stockholder approval; private placement closes immediately after merger.
Combined pipeline includes SGT-003 for Duchenne, AVB-202 for Friedreich's ataxia, AVB-401 for BAG3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.